Skip to main content

Advertisement

SpringerLink
Log in

Allogeneic Hematopoietic Stem Cell Transplantation: A Salvage Treatment for Relapsed or Refractory Lymphoma

  • Original Article
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

To analyze the efficacy and safety of allogeneic hematopoietic stem cell transplantation (Allo-HSCT) in patients with relapsed or refractory lymphoma, the therapeutic efficacy, safety, and survival of 23 patients were evaluated. There were 18 (78.3 %) patients with relapsed lymphoma and 5 (21.7 %) patients with refractory lymphoma. Patients were grafted from human leukocyte antigen (HLA)-matched (10) or mismatched (7) related donors, or matched unrelated donors (6). The responses after Allo-HSCT included 13 (56.5 %) cases of complete remission, 5 (21.7 %) cases of partial remission, and 5 (21.7 %) cases of progressive disease. Overall, 16 of 23 patients were alive at a median follow up of 1,035 days (range 60–2,613), five patients died because of non-relapsed mortality, and two patients died of progressive disease. Progression-free survival rates were 64.6 and 48.4 % at 12 and 24 months, respectively, and overall survival rates were 68.6 and 59.5 % at 12 and 24 months, respectively. Allo-HSCT may be a salvage treatment for relapsed or refractory lymphoma. Myeloablative conditioning regimens may be effective and safe.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Gopal AK, Press OW, Shustov AR, Petersdorf SH, Gooley TA, Daniels JT et al (2010) Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multicenter phase II study by the puget sound oncology consortium. Leuk Lymphoma 51:1523–1529

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Rigacci L, Fabbri A, Puccini B, Chitarrelli I, Chiappella A, Vitolo U et al (2010) Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin) ± rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma. Cancer 116:4573–4579

    Article  CAS  PubMed  Google Scholar 

  3. Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G et al (2006) High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. Leuk Lymphoma 47:1545–1552

    Article  CAS  PubMed  Google Scholar 

  4. Freytes CO, Loberiza FR, Rizzo JD, Bashey A, Bredeson CN, Cairo MS et al (2004) Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the international bone marrow transplant registry. Blood 104:3797–3803

    Article  CAS  PubMed  Google Scholar 

  5. Bertz H, Illerhaus G, Veelken H, Finke J (2002) Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens. Ann Oncol 13:135–139

    Article  CAS  PubMed  Google Scholar 

  6. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphoma. J Clin Oncol 17:1244

    CAS  PubMed  Google Scholar 

  7. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al (1995) Consensus conference on acute GVHD grading. Bone Marrow Transpl 15:825–828

    CAS  Google Scholar 

  8. Thomas ED (1999) A history of haemopoietic cell transplantation. Br J Haematol 105:330–339

    Article  CAS  PubMed  Google Scholar 

  9. Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L et al (2005) Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and nonmethotrexate containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transpl 11:383–388

    Article  CAS  Google Scholar 

  10. Petersen FB, Appelbaum FR, Bigelow CL, Buckner CD, Clift RA, Sanders JE et al (1989) High-dose cytosine arabinoside, total body irradiation and marrow transplantation for advanced malignant lymphoma. Bone Marrow Transpl 4:483–488

    CAS  Google Scholar 

  11. Chopra R, Goldstone AH, Pearce R, Philip T, Petersen F, Appelbaum F et al (1992) Autologous versus allogeneic bone marrow transplantation for non-Hodgkin’s lymphoma: a case-controlled analysis of the European bone marrow transplant group registry data. J Clin Oncol 10:1690–1695

    CAS  PubMed  Google Scholar 

  12. Le Gouill S, Mohty M, Guillaume T, Gsatinne T, Moreau P (2011) Allogeneic stem cell transplantation in mantle cell lymphoma: where are we now and which way should we go? Semin Hematol 48:227–239

    Article  PubMed  Google Scholar 

  13. van Besien K, Loberiza FR Jr, Bajorunaite R, Armitage JO, Bashey A, Burns LJ et al (2003) Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102:3521–3529

    Article  PubMed  Google Scholar 

  14. Bloor AJ, Thomson K, Chowdhry N, Verfuerth S, Ings SJ, Chakraverty R et al (2008) High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transpl 14:50–58

    Article  Google Scholar 

  15. Sohn SK, Jung JT, Kim DH, Lee NY, Seo KW, Chae YS et al (2002) Prophylactic growth factor-primed donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies. Cancer 94:18–24

    Article  CAS  PubMed  Google Scholar 

  16. Sznol M, Parkinson DR (1994) Interleukin-2 in therapy of hematologic malignancies. Blood 83:2020–2022

    CAS  PubMed  Google Scholar 

  17. Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Gastineau DA et al (2008) Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transpl 14:807–816

    Article  Google Scholar 

  18. Sykes M, Harty MW, Szot GL, Pearson DA et al (1994) Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects. Blood 83:2560–2569

    CAS  PubMed  Google Scholar 

  19. Robb RJ, Geoffrey R, Hill GR (2012) The interferon-dependent orchestration of innate and adaptive immunity after transplantation. Blood 119:5351–5358

    Article  CAS  PubMed  Google Scholar 

  20. Ramos CA, Saliba RM, de Pádua SL, Khorshid O, Shpall EJ, Giralt S et al (2010) Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl 16:686–694

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Beijing Friendship Hospital, Capital Medical University, No. 95 Yong’an Road, Xicheng District, Beijing, 100050, People’s Republic of China

    Jing-Shi Wang, Zhao Wang, Yi-Ni Wang, Lin Wu, Li Fu & Na Wei

Authors
  1. Jing-Shi Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yi-Ni Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lin Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Li Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Na Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhao Wang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, JS., Wang, Z., Wang, YN. et al. Allogeneic Hematopoietic Stem Cell Transplantation: A Salvage Treatment for Relapsed or Refractory Lymphoma. Indian J Hematol Blood Transfus 31, 426–433 (2015). https://doi.org/10.1007/s12288-014-0497-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-014-0497-7

Keywords

Search

Navigation